Author: Collin D. Heer; Daniel J. Sanderson; Yousef M.O. Alhammad; Mark S. Schmidt; Samuel A.J. Trammell; Stanley Perlman; Michael S. Cohen; Anthony R. Fehr; Charles Brenner
Title: Coronavirus Infection and PARP Expression Dysregulate the NAD Metabolome: A Potentially Actionable Component of Innate Immunity Document date: 2020_4_18
ID: 033phqmd_42
Snippet: Though the focus of this preclinical work is prevention, we note that innate immune responses to CoV infection, like other inflammatory responses, are potentially pathological if infection is not controlled. COVID-19 patients with acute respiratory distress syndrome experience a cytokine storm that features high level circulation of inflammatory cytokines (Mehta et al., 2020) . Interestingly, in a small placebo-controlled clinical trial designed .....
Document: Though the focus of this preclinical work is prevention, we note that innate immune responses to CoV infection, like other inflammatory responses, are potentially pathological if infection is not controlled. COVID-19 patients with acute respiratory distress syndrome experience a cytokine storm that features high level circulation of inflammatory cytokines (Mehta et al., 2020) . Interestingly, in a small placebo-controlled clinical trial designed to address the oral safety and activity of Niagen NR in older men, it was discovered that 1 gram of NR per day depresses levels of IL-6, IL-5, IL-2 and tumor necrosis factor alpha (Elhassan et al., 2019) , suggesting the possibility that Niagen and other NAD boosters may also be tested for safety, control of cytokine storm, and modulation of COVID-19 disease in patients.
Search related documents:
Co phrase search for related documents- acute respiratory distress syndrome experience and cytokine storm: 1, 2
- acute respiratory distress syndrome experience and immune response: 1, 2
- acute respiratory distress syndrome experience and inflammatory cytokine: 1, 2
- acute respiratory distress syndrome experience and inflammatory response: 1, 2
- clinical trial and CoV infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical trial and CoV infection immune response: 1, 2, 3, 4
- clinical trial and cytokine storm: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical trial and cytokine storm control: 1
- clinical trial and high level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical trial and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical trial and infection control: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical trial and inflammatory cytokine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- clinical trial and inflammatory response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical trial and necrosis factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical trial and necrosis factor alpha: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- CoV infection and cytokine storm: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- CoV infection and high level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- CoV infection and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- CoV infection and infection control: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date